BRIEF-Spark says announces publication of positive follow-up data from phase 1 trial of voretigene neparvovec in The Lancet
July 01, 2016 at 07:38 AM EDT
* Says has initiated a rolling submission of bla with fda on voretigene neparvovec
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.